Equities

Merck Tbk PT

MERK:JKT

Merck Tbk PT

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (IDR)4,030.00
  • Today's Change20.00 / 0.50%
  • Shares traded60.20k
  • 1 Year change-17.42%
  • Beta1.2582
Data delayed at least 10 minutes, as of Apr 25 2024 09:48 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

PT Merck Tbk is an Indonesia-based vibrant science and technology company. The Company delivers personalized treatments for serious diseases and enable people to achieve their dream of becoming parents. The Company operates through three segments: Biopharma (ethical products), Consumer Health (over-the-counter products) and Others.

  • Revenue in IDR (TTM)961.43bn
  • Net income in IDR178.24bn
  • Incorporated1970
  • Employees390.00
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Phapros Tbk PT1.07tn-4.21bn418.32bn1.49k--0.57249.190.3902-5.01-5.011,276.14869.980.56941.791.75708,496,600.00-0.22873.51-0.41046.8250.0552.91-0.40166.060.86480.85450.5308--11.133.12153.55-25.86-29.64--
Indofarma Tbk PT684.91bn-437.05bn418.40bn1.09k------0.6109-141.03-141.03221.00-33.990.41473.143.13578,473,800.00-26.46-6.07-75.37-12.29-25.7314.39-63.81-5.630.4962-15.511.16---60.58-6.85-1,040.12---32.32--
Ikapharmindo Putramas Tbk PT-100.00bn-100.00bn539.09bn983.00------------------------------------------------4.68--104.02------
Darya-Varia Laboratoria Tbk PT1.89tn146.34bn1.58tn1.27k10.831.137.540.8381130.66130.661,688.291,253.960.93351.913.011,490,061,000.007.228.459.5511.4151.5852.217.748.831.9651.880.001---1.362.16-2.03-6.1216.57--
Merck Tbk PT961.43bn178.24bn1.80tn390.0010.082.268.531.87397.85397.852,146.061,776.520.96361.508.082,465,215,000.0017.8612.7821.8518.1241.6540.5318.5414.062.73--0.0223---14.519.46-0.888436.67-3.13--
Pyridam Farma Tbk PT702.07bn-85.22bn1.82tn1.19k--1.13--2.59-34.19-34.19281.70143.180.46161.874.16588,489,200.00-5.606.31-6.968.0742.0642.56-12.148.831.170.02080.7343---1.8722.89-130.96--2.93--
Kimia Farma Tbk PT10.19tn-151.01bn4.20tn11.56k--0.52156.860.4125-27.14-29.921,832.231,447.630.51971.994.03875,986,400.00-0.20640.9731-0.36991.6238.1036.45-0.39721.520.57651.250.4588---25.299.41-151.14---4.56--
Soho Global Health Tbk PT8.20tn371.34bn6.24tn2.37k16.822.6014.200.761729.2629.26645.92189.031.785.436.153,454,595,000.008.057.9714.4614.3715.9319.394.534.651.26--0.0083--12.4512.434.1049.7021.21--
Tempo Scan Pacific Tbk PT13.12tn1.18tn8.68tn4.54k7.381.135.550.6617260.77260.772,908.251,706.911.164.379.032,889,820,000.0011.049.5615.6013.1235.8535.919.537.852.03--0.1216--7.065.4017.5518.12-6.87--
Data as of Apr 25 2024. Currency figures normalised to Merck Tbk PT's reporting currency: Indonesian Rupiah IDR

Institutional shareholders

0.65%Per cent of shares held by top holders
HolderShares% Held
Samarang LLPas of 30 Jun 20222.92m0.65%
Data from 30 Jun 2022 - 30 Jun 2022Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.